Department of Applied Biomedical Science, Faculty of Health Sciences, University of Malta, Msida, Malta.
Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta.
Endocrinol Diabetes Metab. 2023 May;6(3):e408. doi: 10.1002/edm2.408. Epub 2023 Feb 9.
Adipose tissue is the source of a broad array of signalling molecules (adipokines), which mediate interorgan communication and regulate metabolic homeostasis. Alterations in adipokine levels have been causally implicated in various metabolic disorders, including changes in bone mass. Osteoporosis is the commonest progressive metabolic bone disease, characterized by elevated risk of fragility fractures as a result of a reduced bone mass and microarchitectural deterioration. The effects of different adipokines on bone mass have been studied in an attempt to identify novel modulators of bone mass or diagnostic biomarkers of osteoporosis.
In this review, we sought to aggregate and assess evidence from independent studies that quantify specific adipokines and their effect on bone mineral density (BMD).
A literature search identified 57 articles that explored associations between different adipokines and BMD. Adiponectin and leptin were the most frequently studied adipokines, with most studies demonstrating that adiponectin levels are associated with decreased BMD at the lumbar spine and femoral neck. Conversely, leptin levels are associated with increased BMD at these sites. However, extensive heterogeneity with regards to sample size, characteristics of study subjects, ethnicity, as well as direction and magnitude of effect at specific skeletal anatomical sites was identified. The broad degree of conflicting findings reported in this study can be attributed several factors. These include differences in study design and ascertainment criteria, the analytic challenges of quantifying specific adipokines and their isoforms, pre-analytical variables (in particular patient preparation) and confounding effects of co-existing disease.
This review highlights the biological relevance of adipokines in bone metabolism and reinforces the need for longitudinal research to elucidate the causal relationship of adipokines on bone mass.
脂肪组织是一系列信号分子(脂肪因子)的来源,这些分子介导器官间的通讯并调节代谢稳态。脂肪因子水平的改变与各种代谢紊乱有关,包括骨量的变化。骨质疏松症是最常见的进行性代谢性骨病,其特征是由于骨量减少和微结构恶化,脆性骨折的风险增加。已经研究了不同脂肪因子对骨量的影响,试图确定骨量的新型调节剂或骨质疏松症的诊断生物标志物。
在本综述中,我们试图汇总和评估独立研究的证据,这些研究量化了特定的脂肪因子及其对骨密度(BMD)的影响。
文献检索确定了 57 篇探讨不同脂肪因子与 BMD 之间关系的文章。脂联素和瘦素是研究最多的脂肪因子,大多数研究表明,脂联素水平与腰椎和股骨颈的骨密度降低有关。相反,瘦素水平与这些部位的骨密度增加有关。然而,在样本量、研究对象特征、种族以及特定骨骼解剖部位的作用方向和幅度方面,存在广泛的异质性。本研究报告的大量相互矛盾的发现可以归因于几个因素。这些因素包括研究设计和确定标准的差异、量化特定脂肪因子及其同工型的分析挑战、预分析变量(特别是患者准备)以及共存疾病的混杂影响。
本综述强调了脂肪因子在骨代谢中的生物学相关性,并强调需要进行纵向研究以阐明脂肪因子对骨量的因果关系。